Seeing into the future: Personalized cancer screening with artificial intelligence
Scientists demonstrate that AI-risk models, paired with AI-designed screening policies, can offer significant and equitable improvements to cancer screening.
Scientists demonstrate that AI-risk models, paired with AI-designed screening policies, can offer significant and equitable improvements to cancer screening.
Cardiologist Demilade Adedinsewo is using her MIT Professional Education experience to advance cardiovascular care at the Mayo Clinic.
Scientists employ an underused resource — radiology reports that accompany medical images — to improve the interpretive abilities of machine learning algorithms.
Neural network identifies synergistic drug blends for treating viruses like SARS-CoV-2.
MIT researchers employ machine learning to find powerful peptides that could improve a gene therapy drug for Duchenne muscular dystrophy.
Nearly 300 government and military members participated in a new course designed to explore the next generation of artificial intelligence and related technologies.
Nearly 1,400 joined the AI for Health Care Equity Conference that explored new AI technologies as a platform for change.
A machine learning model developed jointly by Janssen and MIT data scientists played a key role in the clinical trial process for the Johnson & Johnson Covid-19 vaccine.
Using deep convolutional neural networks, researchers devise a system that quickly analyzes wide-field images of patients’ skin in order to more efficiently detect cancer.
Regina Barzilay, Fotini Christia, and Collin Stultz describe how artificial intelligence and machine learning can support fairness, personalization, and inclusiveness in health care.
MIT conference illustrates technologies developed in response to the pandemic and new opportunities for AI solutions for clinical management.
Research projects will harness the power of artificial intelligence to positively impact human health.
Inaugural AI Powered Drug Discovery and Manufacturing Conference drew pharmaceutical companies, government regulators, and pioneering drug researchers.
A deep-learning model identifies a powerful new drug that can kill many species of antibiotic-resistant bacteria.
A key part of J-Clinic, the MIT-Takeda Program will create educational opportunities and support cutting-edge research to positively impact human health.